Top

Published in:

Open Access 01-12-2022 | Lung Cancer | Case report

Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report

Authors: Shreya Tripathy, Nathaniel Alvarez, Shubham Jaiswal, Ryan Williams, Munaf Al-Khadimi, Sarah Hackman, William Phillips, Supreet Kaur, Sherri Cervantez, William Kelly, Josephine Taverna

Published in: Journal of Medical Case Reports | Issue 1/2022

Abstract

Background

Given the current climate of the pandemic, lung cancer patients are especially vulnerable to complications from severe acute respiratory syndrome coronavirus 2 infection. As a high-risk population group, these patients are strongly advised to receive coronavirus disease 2019 vaccination in accordance with Center for Disease Control and Prevention guidelines to minimize morbidity and mortality. In recent years, immunotherapy has taken a preeminent role in the treatment of non-small cell lung cancer with dramatic improvement in overall survival. Reactive lymphadenopathy following the administration of a coronavirus disease 2019 vaccination can confound the radiographic interpretation of positron emission tomography–computed tomography or computed tomography scans from lung cancer patients receiving immunotherapy.

Case presentation

Here, we present a case of a 61-year-old Caucasian female and former smoker who developed cervical, hilar, supraclavicular, mediastinal, and left retroauricular lymphadenopathy following her coronavirus disease 2019 booster vaccination. At the time, she had been receiving long-term immunotherapy for the treatment of advanced lung adenocarcinoma. Biopsy was pursued owing to concerns of treatment failure and confirmed recurrent malignancy.

Conclusion

This case report highlights the importance of lymph node biopsies in lung cancer patients who present with contralateral lymphadenopathy following coronavirus disease 2019 vaccination to rule out tumor recurrence in this deserving patient population.

Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753–8. https://doi.org/10.1136/postgradmedj-2020-138234.CrossRefPubMed

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/s0140-6736(20)30566-3.CrossRefPubMedPubMedCentral

Faggiano P, Bonelli A, Paris S, Milesi G, Bisegna S, Bernardi N, et al. Acute pulmonary embolism in COVID-19 disease: preliminary report on seven patients. Int J Cardiol. 2020;313:129–31. https://doi.org/10.1016/j.ijcard.2020.04.028.CrossRefPubMedPubMedCentral

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901. https://doi.org/10.1016/j.annonc.2020.03.296.CrossRefPubMed

Kommoss FKF, Schwab C, Tavernar L, Schreck J, Wagner WL, Merle U, et al. The pathology of severe COVID-19-related lung damage. Dtsch Arztebl Int. 2020;117(29–30):500–6.PubMed

Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021;9(3):e002266. https://doi.org/10.1136/jitc-2020-002266.CrossRefPubMedPubMedCentral

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91. https://doi.org/10.1158/2159-8290.Cd-20-0422.CrossRefPubMedPubMedCentral

Food and Drug Administration US. COVID-19 vaccinations 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines. Updated 7 Jan 2022; Accessed 1 Jan 2022.

Centers for Disease Control and Prevention US. COVID-19 vaccines for moderately or severely immunocompromised people 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html. Updated 7 Jan 2022; Accessed 9 Jan 2022.

10.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. https://doi.org/10.1056/NEJMoa1801005.CrossRefPubMed

11.

Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881–95. https://doi.org/10.1016/j.annonc.2021.04.008.CrossRefPubMed

12.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/s0140-6736(15)01281-7.CrossRefPubMed

13.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865.CrossRefPubMed

14.

Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E. Pseudoprogression and hyperprogression as new forms of response to immunotherapy. BioDrugs. 2020;34(4):463–76. https://doi.org/10.1007/s40259-020-00425-y.CrossRefPubMed

15.

Cocco G, Delli Pizzi A, Taraschi AL, Boccatonda A, Corvino A, Ucciferri C, et al. Atypical sites of lymphadenopathy after anti-COVID-19 vaccine: ultrasound features. Medicina (Kaunas). 2022;58(2):197. https://doi.org/10.3390/medicina58020197.CrossRefPubMed

16.

Singh B, Kaur P, Kumar V, Maroules M. COVID-19 vaccine induced axillary and pectoral lymphadenopathy on PET scan. Radiol Case Rep. 2021;16(7):1819–21. https://doi.org/10.1016/j.radcr.2021.04.053.CrossRefPubMedPubMedCentral

17.

Doss M, Nakhoda SK, Li Y, Yu JQ. COVID-19 vaccine-related local FDG uptake. Clin Nucl Med. 2021;46(5):439–41. https://doi.org/10.1097/rlu.0000000000003634.CrossRefPubMed

18.

Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy following COVID-19 vaccination: imaging findings review. Acad Radiol. 2021;28(8):1058–71. https://doi.org/10.1016/j.acra.2021.04.007.CrossRefPubMedPubMedCentral

19.

Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021;48(6):1854–63. https://doi.org/10.1007/s00259-021-05314-2.CrossRefPubMedPubMedCentral

20.

McIntosh LJ, Bankier AA, Vijayaraghavan GR, Licho R, Rosen MP. COVID-19 vaccination-related uptake on FDG PET/CT: an emerging dilemma and suggestions for management. Am J Roentgenol. 2021;217(4):975–83. https://doi.org/10.2214/ajr.21.25728.CrossRef

21.

McIntosh LJ, Rosen MP, Mittal K, Whalen GF, Bathini VG, Ali T, et al. Coordination and optimization of FDG PET/CT and COVID-19 vaccination; lessons learned in the early stages of mass vaccination. Cancer Treat Rev. 2021;98:102220. https://doi.org/10.1016/j.ctrv.2021.102220.CrossRefPubMedPubMedCentral

22.

Lehman CD, Lamb LR, D’Alessandro HA. Mitigating the impact of coronavirus disease (COVID-19) vaccinations on patients undergoing breast imaging examinations: a pragmatic approach. Am J Roentgenol. 2021;217(3):584–6. https://doi.org/10.2214/ajr.21.25688.CrossRef

23.

Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsi M, Feigin KN, et al. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel. Radiology. 2021;300(2):E323–7. https://doi.org/10.1148/radiol.2021210436.CrossRefPubMed

24.

Lasagna A, Lilleri D, Agustoni F, Percivalle E, Borgetto S, Alessio N, et al. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up. ESMO Open. 2022;7(1):100359. https://doi.org/10.1016/j.esmoop.2021.100359.CrossRefPubMed

25.

Khalifehzadeh-Esfahani Z, Fattahi S, Heidari Haratemeh Z, Jafarinia M. The role of immune regulatory molecules in COVID-19. Viral Immunol. 2022;35(5):359–64. https://doi.org/10.1089/vim.2021.0211.CrossRefPubMed

26.

Al-Mterin MA, Alsalman A, Elkord E. Inhibitory immune checkpoint receptors and ligands as prognostic biomarkers in COVID-19 patients. Front Immunol. 2022;13:870283. https://doi.org/10.3389/fimmu.2022.870283.CrossRefPubMedPubMedCentral

27.

Rha MS, Jeong HW, Ko JH, Choi SJ, Seo IH, Lee JS, et al. PD-1-expressing SARS-CoV-2-specific CD8(+) T cells are not exhausted, but functional in patients with COVID-19. Immunity. 2021;54(1):44-52.e3. https://doi.org/10.1016/j.immuni.2020.12.002.CrossRefPubMed

28.

Mortezaee K, Majidpoor J. CD8(+) T cells in SARS-CoV-2 induced disease and cancer-clinical perspectives. Front Immunol. 2022;13:864298. https://doi.org/10.3389/fimmu.2022.864298.CrossRefPubMedPubMedCentral

29.

Vivarelli S, Falzone L, Leonardi GC, Salmeri M, Libra M. Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). Int J Oncol. 2021;59(3):75. https://doi.org/10.3892/ijo.2021.5255.CrossRefPubMedPubMedCentral

30.

Mei Q, Hu G, Yang Y, Liu B, Yin J, Li M, et al. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study. J Immunother Cancer. 2022;10(3):4157. https://doi.org/10.1136/jitc-2021-004157.CrossRef

Title: Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report
Authors: Shreya Tripathy
Nathaniel Alvarez
Shubham Jaiswal
Ryan Williams
Munaf Al-Khadimi
Sarah Hackman
William Phillips
Supreet Kaur
Sherri Cervantez
William Kelly
Josephine Taverna
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
COVID-19 Vaccination
Vaccination
COVID-19
Lung Cancer
Lymphadenopathy
Published in: Journal of Medical Case Reports / Issue 1/2022
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/s13256-022-03660-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report

Abstract

Background

Case presentation

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Management of giant osteoma in the mandible associated with minor trauma: a case report

Transplantation of autologous cultivated oral mucosal epithelial sheets for limbal stem cell deficiency at Siriraj Hospital: a case series

Ectopic intrathyroidal thymic tissue in an adult patient: a case report and review of the literature

The association between adult-onset Still’s disease and collapsing glomerulopathy: a case report

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report

Avascular necrosis of the talus causing meniscoid lesions in the ankle joint: a case report